Sylentis’ pipeline is directed towards indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases.
********************
ECCO : EUROPEAN CROHN,S AND COLITIS ORGANISATION .
SE PUEDE YA AFIRMAR QUE TARLATAMAB ( IMDELLTRA BY AMGEN ) SUPERA AMPLIAMENTE AL LURBINECTEDIN ( ZEPZELCA BY PHARMAMAR ) TANTO EN PRIMERA LÍNEA DE MANTENIMIENTO ... COMO EN SEGUNDA LINEA PARA EL TRATAMIENTO ESTÁNDAR DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE .